Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and greater muscle loss is independently associated with less improvement in glucose ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the ...

It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high. Shares of Novo Nordisk and ...

Patients put on weight loss drugs like Ozempic and Wegovy may start regaining weight within weeks of discontinuing them, a ...

We can't have it both ways. If we want more cutting-edge drugs, we have to protect the property rights that make them ...

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Patients regain weight after stopping weight loss drugs, long-term success may depend on lifestyle and drug choice.

Willingness to try new drugs for obesity management have propelled the growth of this market, which today is almost five ...

Everyone aspires to live a healthy life. The catch is that health is a moving target. It’s a challenge that changes as people ...